are neurotoxicity and parkinsonism causes for concern?

U.S.-based pharmaceutical firm Galapagos has suspended the enrolment of patients in a phase 1/2 trial of its Chimeric antigen receptor (CAR)-T therapy candidate GLPG5301 following a patient displaying signs of parkinsonism. Meanwhile, the FDA-approved Carvykti has also been linked to a risk of developing parkinsonism and Guillain-Barré syndrome. Current CAR-T therapies for cancer and autoimmune diseases are coming under scrutiny due to the potential for serious side effects, including neurotoxicities.